In this video interview, Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at the Northwestern ...

In this video interview, Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at the Northwestern ...

More than 31 million Americans are living with eczema/ atopic dermatitis (AD), a chronic inflammatory skin condition that extends far beyond visible symptoms to disrupt sleep, mental health, and daily ...

NEMLUVIO is the first authorized monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has ...

Delgocitinib cream and dupilumab have similar efficacy at 16 weeks of treatment in patients with moderate to severe atopic hand eczema.

SaveHealth reports on eczema medications, detailing various options from topical treatments to advanced therapies for ...

Maybe your child has been on a specific treatment for atopic dermatitis (also called eczema) for months or even years, but now flare-ups seem to be happening more often and with greater intensity. Or ...

Tralokinumab plus optional use of TCS or TCI in adults with moderate to severe AD was associated with stable disease control for up to 4 years.

Researchers have found in a new real-world study that dupilumab was an effective and safe therapeutic option for head and ...

J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory ...